Search Results for "Zolidronic Mdscs"
Original Source: Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.
Background:Suppressive immune cells present in tumour microenvironments are known to augment tumour growth and hamper efficacy of antitumour therapies. The amino-bisphosphonate Zoledronic acid (ZA) is considered as an antitumour agent, as recent studies showed that ZA prolongs disease-free survival in cancer patients. The exact mechanism is a topic of debate; it has been suggested that ZA targets tumour-associated macrophages (TAMs).Methods:We investigate the role of ZA on the myeloid differentiation to TAM...
Matching Channels
None
Matching News
Gabrilovich and colleagues show that monocytic myeloid-derived suppressor cells (MDSCs) differentiate into polymorphonuclear MDSCs in individuals with tumors, demonstrating a distinct regulation of my...
Gemcitabine and 5-fluorouracil are two commonly used chemotherapeutic agents for the treatment of cancer. François Ghiringhelli and colleagues now report that the antitumor efficacy of these agents i...
Tumour immunology: Suppressing the rejection of pancreatic tumours
KRAS-transformed pancreatic tumour cells produce GM-CSF, which recruits MDSCs to promote an immunosuppressive microenvironment.
Microenvironment: Suppressing the rejection of pancreatic tumours
Two papers show that KRAS-G12D-transformed pancreatic tumour cells produce GM-CSF, which recruits MDSCs to promote an immunosuppressive microenvironment.
Advaxis Reports Updated Phase 2 Cervical Cancer Trial Data at NCI/GOG Meeting
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, presented updated preliminary data from an o...
Advaxis Updates Phase 2 Cervical Cancer Trial Data
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, updated preliminary data from an ongoing ran...
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, will update preliminary data on the safety a...
Matching PubMed Articles
Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity.
Myeloid-derived suppressor cells (MDSCs) are primarily recognized for their immunosuppressive properties in malignant disease. However, their interaction with other innate immune cells and their regul...
Neutrophils are essential effector cells in the host defense against invading pathogens. Recently, novel neutrophil functions have emerged in addition to their classical anti-microbial role. One of th...
Myeloid-derived suppressor cells control microbial sepsis.
PURPOSE: To investigate the role of myeloid-derived suppressor cells (MDSCs) during sepsis in mice. MDSCs are a heterogeneous population of cells that expand during cancer, inflammation and infection....
Multilineage differentiation of muscle-derived stem cells from GFP transgenic mice.
It is unclear whether green fluorescent protein (GFP) expression is maintained during the course of multilineage differentiation of muscle-derived stem cells (MDSCs). We isolated MDSCs from GFP-transg...
A novel chemoimmunomodulating property of Docetaxel: suppression of MDSC in tumor bearers.
PURPOSE: Myeloid derived suppressor cells (MDSCs) accumulate in tumor bearing hosts and are associated with immune suppression. To date, there have only been few studies that evaluate the direct effec...
